GBLP — Global Pharmatech Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $20.76m
- $19.16m
- $2.82m
Annual income statement for Global Pharmatech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2003 March 31st | 2004 March 31st | 2005 December 31st | R2006 December 31st | 2007 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10KSB | 10KSB | 10KSB | 10KSB | 10KSB |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 3.08 | 2.13 | 2.82 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 1.69 | 1.6 | 1.32 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0 | 0 | 3.46 | 3.4 | 5.31 |
| Operating Profit | 0 | 0 | -0.379 | -1.28 | -2.49 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0 | 0 | 0.128 | -0.901 | -2.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0 | 0 | 0.127 | -0.901 | -2.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -0.607 | -0.035 | 0.2 | -1.23 | -3.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.607 | -0.035 | 0.2 | -1.23 | -3.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0 | 0 | 0.011 | -0.047 | -0.105 |
| Dividends per Share |